Welcome to our dedicated page for Medipharm Labs news (Ticker: MEDIF), a resource for investors and traders seeking the latest updates and insights on Medipharm Labs stock.
MediPharm Labs Corp (MEDIF) is a leader in pharmaceutical-grade cannabis extraction and precision cannabinoid manufacturing, serving global medical markets through GMP-certified facilities. This page aggregates official news and verified updates about the company’s strategic initiatives, regulatory compliance milestones, and international expansion efforts.
Investors and industry professionals will find timely reports on earnings, partnership announcements, product innovations, and quality control advancements. Our curated collection simplifies tracking MEDIF’s progress in developing non-combustible delivery systems and expanding into regulated markets like Germany and Australia.
All content is sourced from company releases and accredited financial publications to ensure accuracy. Bookmark this page for streamlined access to MEDIF’s latest developments in pharmaceutical cannabis manufacturing, B2B white-label services, and API production.
MediPharm Labs Corp. (OTCQX: MEDIF) announced the results of its annual meeting held on June 9, 2021. A total of 361 shareholders representing 25.29% of common shares participated. All nominees for director were elected, with Warren Everitt receiving the highest votes of 44,825,123. KPMG LLP was appointed as the company’s auditor. MediPharm Labs specializes in pharmaceutical-quality cannabis extraction and has seen success in international markets, including commercial exports to Australia, generating revenues since H1 2020.
MediPharm Labs Corp. has renewed its supply agreement with ADREXpharma for five years, extending their partnership in the German medical cannabis market, which experienced a 34% sales increase in 2020. MediPharm aims to capitalize on the growing demand, with 128,000 active patients spending an average of $500 EUR monthly. The company successfully shipped its first cannabis products to Germany in Q1 2021 and is set to deliver subsequent shipments in Q2 2021, consolidating its position as a trusted supplier in a burgeoning market.
MediPharm Labs (OTCQX: MEDIF) has launched its first wellness products in Quebec, marking a significant expansion into one of Canada’s largest consumer markets.
The company shipped its first order of premium CBD oils to the Société québécoise du cannabis (SQDC) for retail sale. This launch represents the seventh provincial distribution agreement for MediPharm, enhancing its presence across 95% of the Canadian retail market.
MediPharm Labs (OTCQX: MEDIF) announced the launch of its first wellness products in Quebec, including premium CBD oils, marking a significant expansion in its Canadian operations. This shipment to the Société québécoise du cannabis (SQDC) represents the company's entry into Quebec, its seventh provincial distribution agreement, enabling access to 95% of the retail market in Canada. The company aims to enhance its local presence as the Canadian market begins recovering. MediPharm Labs specializes in high-quality cannabis extraction and has commercial exports to Australia.
MediPharm Labs (OTCQX: MEDIF) reported Q1 2021 results with revenues of $5.5 million, a 9% decline from Q4 2020. International sales rose to $2.1 million, offset by a 40% drop in Canadian sales due to pandemic-related challenges. The company achieved initial sales of GMP-certified products in Germany and entered the Latin American market with shipments to Peru. Notably, MediPharm reduced costs by 30%, improving financial efficiency. Cash reserves stood at $42.1 million as of March 31, 2021, supporting strategic growth initiatives.
MediPharm Labs Corp. (OTCQX: MEDIF) will release its first quarter financial results for the period ended March 31, 2021, before the market opens on May 17, 2021. An audio conference call will follow at 8:30 a.m. ET to discuss the results and outlook. The company specializes in producing pharmaceutical-quality cannabis products and is recognized for its advanced extraction techniques. MediPharm has commercialized its extraction facility in Australia and focuses on research-driven product development.
MediPharm Labs Corp. (OTCQX: MEDIF) has signed a two-year agreement with MT Pharma to supply GMP certified cannabis oil for patient distribution. This agreement underscores MediPharm's growth potential in the international pharmaceutical cannabis market, as they expand their customer base across 9 countries. The company has recently completed exports to Germany, Peru, and Australia, and anticipates further international expansion in 2023, including Brazil and New Zealand. MediPharm Labs emphasizes its commitment to high-quality, pharmaceutical-grade products in a rapidly evolving cannabis marketplace.
IM Cannabis Corp. (CSE:IMCC)(NASDAQ:IMCC) announced a two-year supply agreement with MediPharm Labs to enhance its product offerings in Germany. This agreement allows IMC's subsidiary, Adjupharm, to introduce a new range of IMC-branded extracts, including high THC and balanced THC/CBD oils. The products are expected to launch in the second half of 2021, targeting the growing demand for medical cannabis. The partnership aims to strengthen IMC's position as a leader in the expanding German extracts market while fulfilling patient needs.
MediPharm Labs has successfully exported its high THC medical cannabis to Peru, marking its first shipment to a Latin American country. This step follows successful exports to Australia and Germany. The shipment, handled by Cann Farm Peru S.A.C., aims to provide patients with consistent access to quality THC products, which are essential for addressing varied therapeutic needs.
Peru's medical cannabis market is rapidly advancing, offering significant growth potential for MediPharm Labs as it expands operations into Latin America.
MediPharm Labs has successfully exported its first shipment of medical cannabis oil products to Germany, approved by the Australian Therapeutic Goods Administration (TGA). This achievement marks a significant milestone for both the company and Australia, establishing them as leaders in the global medical cannabis market. With Germany representing an estimated 75% of the EU medical cannabis market, MediPharm Labs aims to continue shipments and innovate its offerings for this valuable market throughout 2021 and beyond.
